Clinical Trial Update: Urinary Tumor DNA-Guided Systemic Immunotherapy for Unresectable Very-High-Risk Non-Muscle-Invasive Bladder Cancer [Phase 2]

View source ↗

Summary

This Phase 2 clinical trial assesses urinary tumor DNA-guided systemic immunotherapy for unresectable very-high-risk non-muscle-invasive bladder cancer and is c…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-muscle Invasive Bladder Cancer

Snippet

Sponsor: Tianjin Medical University Second Hospital | Conditions: Bladder Cancer, Liquid Biopsy | Phase 2 | Status: RECRUITING